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Original ArticleTiotropium Respimat Efficacy and Safety in
Asthma: Relationship to AgeDennis E. Doherty, MD
a
, Eugene R. Bleecker, MD
b
, Petra Moroni-Zentgraf, MD
c
, Liliana Zaremba-Pechmann, PhD
d
, and
Huib A.M. Kerstjens, MD
e Lexington, Ky; Tucson, Ariz; Sydney, Australia; Biberach an der Riss, Germany; and Groningen,
The NetherlandsWhat is already known about this topic? There is a perception that there is a differential response to bronchodilators in
older compared with younger patients with asthma, yet this perception is based on limited data.
What does this article add to our knowledge? The current analyses demonstrate that the bronchodilator efficacy and
safety of tiotropium Respimat is not impacted by age in patients with symptomatic moderate or severe asthma.
How does this impact current management guidelines? These results have important therapeutic implications,
because there is an increase in the aging population worldwide as well as increased prevalence of asthma in older
individuals.BACKGROUND: Data are limited on the differential response
to long-acting bronchodilators in older versus younger adults
with asthma.
OBJECTIVE: To determine whether the response to tiotropium
Respimat differed in older versus younger patients with asthma.
METHODS: Post hoc analyses of 4 randomized, double-blind,
placebo-controlled studies in adults with asthma were carried out.
Two studies compared tiotropium Respimat 5 mg once daily with
placebo, both added to high-dose inhaled corticosteroid (ICS)
plus long-acting b2-agonist (ie, severe asthma). The other 2 eval-
uated tiotropium Respimat 2.5 or 5 mg once daily, salmeterol 50
mg twice daily, or placebo, all added to medium-dose ICS (mod-
erate asthma). Data were analyzed in 2 pools: (1) severe and (2)
moderate asthma. Efficacy end points: trough and peak FEV1;
trough forced vital capacity; Asthma Control Questionnaire total
score and responder percentage, all at week 24. One set of analyses
was performed with age as a continuous covariate; the second was
conducted in categories less than 40, 40 to 60, and more thanaUniversity of Kentucky, Lexington, Ky
bUniversity of Arizona, Tucson, Ariz
cBoehringer Ingelheim Pty. Ltd., Sydney, NSW, Australia
dBoehringer Ingelheim, Biberach an der Riss, Germany
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Research Institute for Asthma and COPD, Groningen, The Netherlands
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RESULTS: Across the age categories, treatment-by-age subgroup
interaction P values for trough FEV1 were .13 and .77 for patients
with severe and moderate asthma, respectively, not indicating
significant impact of age on overall treatment effect, with this
observation replicated in the 2 continuum analyses. The other end
points (including safety) were also not impacted by age.
CONCLUSIONS: Once-daily tiotropium Respimat add-on to
ICS or ICS/long-acting b2-agonist therapy was effective and well
tolerated in patients with asthma independent of age.  2020
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ACQ- Asthma Control Questionnaire
ICS- Inhaled corticosteroidLABA- Long-acting b2-agonistINTRODUCTION
Inhaled corticosteroids (ICSs) are the primary controller ther-
apy recommended for the management of persistent asthma in
adults.1 For patients with more than just occasional symptoms, the
current Global Initiative for Asthma report recommends daily low-
dose ICS alone, or as-needed use of low-dose ICS plus the long-
acting b2-agonist (LABA) formoterol.
1 If this is insufficient to
control a patient’s asthma, the Global Initiative for Asthma rec-
ommends regular use of an ICS-LABA combination, with the ICS
dose gradually increased, and the long-acting muscarinic antago-
nist tiotropium an add-on option for patients with asthma that is
uncontrolled with medium- or high-dose ICS plus LABA. Indeed,
tiotropium Respimat has been shown to be an effective add-on
therapy to ICS plus LABA or to ICS alone in patients with
symptomatic asthma,2-4 and is now approved for use as asthma
maintenance treatment for patients from age 6 years in many
countries, including the United States and throughout the Euro-
pean Union (see local label for further details).
There is a perception that there is a differential response to
bronchodilators in older compared with younger patients with
asthma. This perception is perhaps based on an early study eval-
uating the short-acting b2-agonist albuterol and the short-acting
muscarinic antagonist ipratropium5; to our knowledge, no
studies have evaluated the effect of age on the effectiveness of long-
acting bronchodilators. Because asthma impacts individuals of all
ages, with, for example, the US prevalence of asthma in those 65
years or older (7.8%) being similar to that in children (7.5%),6 the
current post hoc analyses were therefore conducted to evaluate the
response to tiotropium Respimat across the 18 to 75 years age
range of adults with symptomatic moderate or severe asthma,
when added-on to ICS or ICS/LABA maintenance therapy.
METHODS
These are analyses of data from 4 phase III, randomized, double-
blind, placebo-controlled studies. The first 2 studies were
PrimoTinA-asthma (NCT00776984 and NCT00772538), which
compared tiotropium Respimat 5 mg once daily with placebo, both
added to high-dose ICS (800 mg budesonide or equivalent) plus
LABA over 48 weeks.2 The other 2 studies were MezzoTinA-asthma
(NCT01172808 and NCT01172821), which evaluated tiotropium
Respimat 2.5 mg or 5 mg once daily, salmeterol 50 mg twice daily via
hydrofluoroalkane pressurized metered-dose inhaler, or placebo,
individually added to medium-dose ICS (400-800 mg budesonide or
equivalent) over 24 weeks.3 Data were analyzed in 2 pools—one
including the 2 PrimoTinA-asthma (severe asthma) studies, and the
other including the 2 MezzoTinA-asthma (moderate asthma) studies.
Participants
Full inclusion and exclusion criteria for the 4 studies have been
published previously.2,3 In brief, all patients were aged 18 to 75
years, symptomatic (Asthma Control Questionnaire [ACQ] mean
score 1.5), with the diagnosis of asthma having been made before
the age of 40 years, and either lifelong nonsmokers or ex-smokers(<10 pack-years, with no smoking in the year before enrollment).
Patients with a diagnosis of chronic obstructive pulmonary disease
were excluded. All patients provided written informed consent
before any study-related procedure. The studies were approved by
the independent ethics committees or research boards at each
institution, and were performed in accordance with the principles of
the Declaration of Helsinki, and the International Conference on
Harmonization notes for guidance on Good Clinical Practice (ICH/
CPMP/135/95).
Outcomes
Coprimary end points of all 4 studies were trough FEV1 response
(assessed within 10 minutes before study medication), and peak
FEV1 within 3 hours postdose, both at week 24. Secondary end
points included trough forced vital capacity, mean ACQ total score,
and the percentage of ACQ responders (defined as an improvement
in ACQ score of at least 0.5 points from baseline; this was a
coprimary end point in the 2 MezzoTinA-asthma studies) at week
24. The data reported in this article are from post hoc analyses of
these end points, with one set of analyses performed with age as a
continuous covariate (“continuum analyses”) and the second set of
analyses conducted in patients subgrouped in the categories age less
than 40, 40 to 60, and more than 60 years (“subgroup analyses”).
Safety data by age category were also analyzed. Some of the
tiotropium versus placebo data from the subgroup analyses have
previously been published,7,8 but none of the salmeterol data or the
continuum analyses have been published.
Sample size and statistical methods
The analyses presented in this article were not formally powered,
and are post hoc and exploratory in nature.
Three different sets of models were run—1 set for the continuum
analyses and 2 for the subgroup analyses. In all 3 sets, trough and
peak FEV1, trough forced vital capacity, and ACQ total score were
analyzed using mixed-effects models that included “treatment,”
“study,” “visit,” and “treatment-by-visit” as fixed, categorical effects
and “baseline” and “baseline-by-visit” as fixed, continuous covariates
(where “baseline” is the value of the respective variable assessed
predose on day 1); ACQ responder rate was analyzed using logistic
regression models that included “treatment” and “study.” The first
set of models, run for the continuum analyses, was used across the
full age range and included age as a continuous covariate. The sec-
ond set of models was used to obtain the results within the
age subgroups. The third set of models was used across the age
subgroups to derive the interaction P value, and included “age
subgroup” and “age_subgroup-by-treatment” interaction.
RESULTS
Participants
The current analyses included data from 912 patients in
PrimoTinA-asthma and 2100 patients in MezzoTinA-asthma.
Their baseline demographic and disease characteristics are pre-
sented in Table I. The mean age of patients in PrimoTinA-
asthma was 53.0 years, and in MezzoTinA-asthma 43.1
years.2,3 Other than age, the only consistent differences between
the 3 age groups were asthma duration on entry to the studies
and bronchodilator reversibility in liters, but not in percent.
Outcomes
In the continuum analyses, bronchodilator efficacy versus
placebo in terms of trough FEV1 was consistently in favor of








2.5 mg QD (n [ 519)
Tiotropium Respimat
5 mg QD (n [ 517)
Salmeterol 50 mg




<40 y 69 67 209 193 237 217
40-60 y 258 239 259 261 253 258
>60 y 129 150 51 63 51 48
Sex: female, %
<40 y 59 52 56 52 50 53
40-60 y 59 65 66 62 64 62
>60 y 63 59 59 60 63 73
Age (y)
<40 y 31  6 32  6 31  6 31  6 30  6 30  6
40-60 y 51  6 52  6 49  6 49  6 49  6 49  6
>60 y 66  4 66  4 65  4 65  4 65  3 66  4
Body mass index (kg/m2)
<40 y 27  7 27  6 25  6 26  7 25  6 26  7
40-60 y 29  6 29  7 28  6 28  6 28  6 28  6
>60 y 28  5 28  5 29  8 28  5 29  7 28  5
Smoking status, %
Never smoked
<40 y 78 69 87 86 87 94
40-60 y 73 76 82 79 81 81
>60 y 75 83 82 78 69 83
Ex-smoker
<40 y 22 31 13 14 13 6
40-60 y 27 24 18 21 19 19
>60 y 25 17 18 22 31 17
Smoking history (pack-years)
<40 y 4.2  3.1 4.0  2.6 2.5  2.1 4.0  2.5 3.3  2.8 3.4  2.0
40-60 y 5.0  2.6 5.1  2.5 4.8  2.8 4.6  3.3 4.5  2.7 4.0  2.5
>60 y 6.6  2.7 4.5  3.0 4.6  3.6 4.9  2.8 4.6  2.6 6.1  2.6
Duration of asthma (y)
<40 y 20  9 22  8 15  11 14  11 13  10 14  11
40-60 y 27  13 28  13 24  14 26  13 24  13 24  13
>60 y 39  12 41  13 38  12 40  14 39  14 38  12
FEV1 % predicted prebronchodilation*
<40 y 55  12 52  13 74  8 72  8 74  8 74  8
40-60 y 55  12 56  12 72  8 72  8 72  8 73  8
>60 y 54  13 55  12 71  7 71  8 73  8 73  8
FEV1 % predicted postbronchodilation*
<40 y 63  12 59  13 91  10 88  10 90  11 90  10
40-60 y 62  13 63  13 88  11 87  11 89  12 89  11
>60 y 60  13 62  13 89  14 87  16 88  10 88  11
FVC % predicted prebronchodilation*
<40 y 78  16 77  17 93  12 92  13 92  12 93  13
40-60 y 80  16 79  16 95  14 95  14 95  14 97  14
>60 y 80  17 80  17 97  14 97  13 97  14 98  16
FVC % predicted postbronchodilation*
<40 y 86  15 85  15 103  12 102  13 101  12 103  11
40-60 y 88  16 87  16 106  14 106  14 107  15 108  14
>60 y 87  18 91  17 112  19 111  15 110  16 108  17
FEV1/FVC % postbronchodilator
<40 y 63  7 59  8 76  9 74  9 76  10 75  8
40-60 y 60  8 61  8 70  9 70  9 70  9 69  9
>60 y 57  9 56  10 65  11 64  8 66  8 68  9
(continued)
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2.5 mg QD (n [ 519)
Tiotropium Respimat
5 mg QD (n [ 517)
Salmeterol 50 mg




<40 y 0.319  0.257 0.281  0.283 0.579  0.283 0.516  0.236 0.544  0.250 0.552  0.248
40-60 y 0.219  0.201 0.223  0.240 0.456  0.208 0.431  0.204 0.471  0.264 0.445  0.194
>60 y 0.149  0.167 0.186  0.159 0.410  0.231 0.378  0.244 0.374  0.134 0.342  0.143
FEV1 reversibility (%†)
<40 y 19  19 17  18 24  12 22  9 22  10 22  10
40-60 y 15  14 16  17 23  9 21  10 23  12 22  9
>60 y 13  14 15  14 25  14 23  15 21  7 22  9
ICS dose of stable maintenance treatment (mg)z
<40 y 1224  521 1230  544 642  208 634  218 639  223 654  229
40-60 y 1159  545 1181  540 663  220 681  214 660  191 682  213
>60 y 1239  485 1231  580 679  202 682  213 659  186 661  182
BID, Twice daily; FVC, forced vital capacity; QD, once daily.
Treated set (pooled data). All values are mean  SD except where indicated.
*Measured at visit 1(screening).
†Percentage change from pre- to postbronchodilator value.
zBudesonide or equivalent dose.
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2656 DOHERTY ETALtiotropium and not influenced by age (Figure 1, A, shows the
results for patients with severe asthma, with the results for pa-
tients with moderate asthma shown in Figure 1, B). This was also
demonstrated in the subgroup analyses, in which the treatment-
by-age subgroup interaction P values were both nonsignificant
(P ¼ .13 for patients with severe asthma [Figure 1, C], and
P ¼ .77 for patients with moderate asthma [Figure 1, D]).
The analyses of peak FEV1 were similar to trough FEV1, with
no clear influence of age on bronchodilator efficacy in either the
patients with severe asthma (Figure 2, A; see Figure E1, A, in this
article’s Online Repository at www.jaci-inpractice.org) or the
patients with moderate asthma (Figure 2, B, and Figure E1, B),
and nonsignificant treatment-by-age subgroup interactions
(P ¼ .57 and .97 for patients with severe and moderate asthma,
respectively). Furthermore, age did not impact trough forced
vital capacity in patients with severe (Figure 3, A; see Figure E2,
A, in this article’s Online Repository at www.jaci-inpractice.org)
or moderate asthma (Figure 3, B, and Figure E2, B); the
interaction P values were .052 and .47, respectively.
In patients with severe asthma, the effect of the addition of
tiotropium Respimat 5 mg once daily on mean ACQ total score
was not influenced by age, neither in the continuum analysis
(Figure 4, A) nor in the subgroup analysis (see Table E1 in this
article’s Online Repository at www.jaci-inpractice.org), with a
nonsignificant treatment-by-age subgroup interaction (P ¼ .13).
Similarly, in patients with moderate asthma, age did not influ-
ence the effect of tiotropium Respimat on mean ACQ total score
(Figure 4, B; see Table E2 in this article’s Online Repository at
www.jaci-inpractice.org); the overall treatment-by-age subgroup
interaction was nonsignificant (P ¼ .49). In both the subgroup
analysis and the continuum analysis, there was a slight decrease
in salmeterol efficacy with increasing age in patients with
moderate asthma.
In the ACQ responder analyses with continuous age, there
was a slight influence of age in both moderate and severe asthma,
with a trend toward decreasing efficacy with increasing age,
although the low number of patients in the lowest and highestage groups resulted in wide CIs (Figure 5, A and B). In the
subgroup analyses, there was no consistent effect of age on the
efficacy of tiotropium Respimat, neither for patients with severe
asthma (Table E1) nor for patients with moderate asthma
(Table E2), with more than 50% of patients in all age groups
receiving tiotropium Respimat showing clinically relevant
improvements from baseline. For salmeterol, there was a trend to
decreasing efficacy with increasing age in both the continuum
(Figure 5, B) and the subgroup (Table E2) analyses.
Safety
The overall frequencies of adverse events and serious adverse
events with tiotropium Respimat were unaffected by age, with
the percentage of adverse events similar to those observed with
placebo (Table II). Asthma serious adverse events (ie, a flare/
exacerbation of asthma, based on the preferred term “asthma,”
Medical Dictionary for Regulatory Activities version 16.1) were
reported by 38 patients in PrimoTinA-asthma (17 [3.7%] with
tiotropium Respimat 5 mg and 21 [4.6%] with placebo) and 8
patients in MezzoTinA-asthma (2 [0.4%], 1 [0.2%], 2 [0.4%],
and 3 [0.6%] with tiotropium Respimat 2.5 and 5 mg, salme-
terol, and placebo, respectively).2,3 There was no consistent
relationship between age and occurrence of this event (Table II).
DISCUSSION
Although the studies were not specifically designed to evaluate
the effect of age on bronchodilator efficacy or safety in patients
with asthma, these post hoc analyses were designed to provide
useful information about the use of tiotropium in clinical set-
tings. The analyses show that there is no differential age-based
response to tiotropium in patients with moderate asthma who
were symptomatic on medium-dose ICS alone, or in those with
severe asthma not well controlled on combination therapy with
high-dose ICS plus LABA.
The lack of an influence of age on tiotropium efficacy was
especially evident for the lung function end points. Any differ-
ences between age groups were small and not clinically
FIGURE 1. Trough FEV1 at week 24: Adjusted mean treatment-placebo difference continuum analysis in patients with (A) severe asthma
(PrimoTinA-asthma) and (B) moderate asthma (MezzoTinA-asthma), and adjusted mean values and treatment-placebo differences in age
categories in patients with (C) severe asthma (PrimoTinA-asthma) and (D) moderate asthma (MezzoTinA-asthma). BID, Twice daily;QD, once
daily;Sal, salmeterol;Tio, tiotropium.Full analysis set.Pooleddata: (AandC) add-on to ICSplusLABA; (BandD) add-on to ICS.Dataplottedare
adjusted mean treatment-placebo difference and 95% CI in panels A and B, and adjusted mean  SE in panels C and D.
FIGURE 2. Adjusted mean treatment-placebo difference in peak FEV1 at week 24 in patients with (A) severe asthma (PrimoTinA-asthma)
and (B) moderate asthma (MezzoTinA-asthma). BID, Twice daily; QD, once daily; Sal, salmeterol; Tio, tiotropium. Full analysis set. Pooled
data: (A) add-on to ICS plus LABA; (B) add-on to ICS. Data plotted are adjusted mean treatment-placebo difference and 95% CI.
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FIGURE 3. Adjusted mean treatment-placebo difference in trough FVC at week 24 in patients with (A) severe asthma (PrimoTinA-
asthma) and (B) moderate asthma (MezzoTinA-asthma). BID, Twice daily; FVC, forced vital capacity; QD, once daily; Sal, salmeterol; Tio,
tiotropium. Full analysis set. Pooled data: (A) add-on to ICS plus LABA; (B) add-on to ICS. Data plotted are adjusted mean treatment-
placebo difference and 95% CI.
FIGURE 4. Adjusted mean treatment-placebo difference in ACQ total score at week 24 in patients with (A) severe asthma (PrimoTinA-
asthma) and (B) moderate asthma (MezzoTinA-asthma). BID, Twice daily; QD, once daily; Sal, salmeterol; Tio, tiotropium. Full
analysis set. Pooled data: (A) add-on to ICS plus LABA; (B) add-on to ICS. Data plotted are adjusted mean treatment-placebo
difference and 95% CI.
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2658 DOHERTY ETALmeaningful neither in patients with moderate nor in patients
with severe asthma. Furthermore, the continuum analyses
demonstrated no clear or consistent influence of age on lung
function. Similarly, for asthma control, age did not influence the
overall treatment effect of tiotropium in terms of ACQ total
score, neither in the continuum nor in the subgroup analyses. In
the responder continuum analyses, there appeared to be a slight
fall with increasing age in the odds ratio for response to tio-
tropium, both in patients with severe asthma and in those with
moderate disease. However, the percentages of patients with a
clinically relevant improvement in the tiotropium treatment
groups was consistently above 50% in all age categories, with no
indication of an effect of age. In contrast, the percentage of
responders on placebo increased with increasing age in both
disease severities, suggesting that the fall in the odds ratio for
response observed in the continuum analysis was due to anincreasing placebo effect, and not a decrease in tiotropium
efficacy.
As with tiotropium, age did not influence the efficacy of sal-
meterol in terms of the bronchodilator responsiveness end
points. With increasing age there was a gradual (although small)
fall in the effect of salmeterol on ACQ total score and ACQ
responders, in both the continuum and the subgroup analyses.
However, the patient numbers were not balanced across age
groups (with relatively few patients with moderate asthma older
than 60 years), and all interaction P values were nonsignificant,
indicating that overall there was no impact of age on treatment
effect, and so these results should be interpreted with caution.
Indeed, in a previous study in adults with asthma (mean age,
42.2 years), tiotropium and salmeterol had similar effects on
ACQ mean score, although tiotropium had a significantly greater
effect on FEV1.
9
FIGURE 5. Treatment-placebo odds ratio for ACQ response at week 24 in patients with (A) severe asthma (PrimoTinA-asthma) and (B)
moderate asthma (MezzoTinA-asthma). ACQ, Asthma Control Questionnaire; BID, twice daily; QD, once daily; Sal, salmeterol; Tio,
tiotropium. Full analysis set. Pooled data: (A) add-on to ICS plus LABA; (B) add-on to ICS. Data plotted are treatment-placebo odds ratio
and 95% CI.








2.5 mg QD (n [ 519)
Tiotropium Respimat
5 mg QD (n [ 517)
Salmeterol 50 mg




<40 y 73.9 79.1 61.2 58.5 55.3 53.9
40-60 y 73.6 79.9 57.1 59.0 52.2 62.0
>60 y 72.9 81.3 51.0 46.0 60.8 66.7
Asthmax adverse events
<40 y 44.9 50.7 15.8 23.3 20.3 20.7
40-60 y 40.7 53.1 17.8 19.5 17.0 23.6
>60 y 35.7 47.3 5.9 23.8 27.5 18.8
Serious adverse events
<40 y 10.1 6.0 2.4 1.6 1.3 1.8
40-60 y 7.4 8.8 1.9 2.3 1.6 2.7
>60 y 8.5 10.0 3.9 3.2 7.8 6.3
Asthmax serious adverse event
<40 y 8.7 4.5 0.5 0 0 0.5
40-60 y 3.1 5.0 0.4 0 0.8 0.8
>60 y 2.3 4.0 0 1.6 0 0
BID, Twice daily; QD, once daily.
Treated set.
*Pooled data, with percentages calculated using the number of patients in the treatment group and age category as denominator.
†Add-on to ICS plus LABA.
zAdd-on to ICS.
xBased on the preferred term “asthma,” Medical Dictionary for Regulatory Activities version 16.1.
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DOHERTY ETAL 2659There is a perception that b2-agonists are more effective in
younger patients, whereas muscarinic antagonists may be more
effective in older patients. Some early preclinical studies sug-
gested that age had an impact on the activity or function of b2 or
muscarinic receptors,10-14 although this was not found in other
preclinical studies.15,16 The perception of differential efficacy is
perhaps based on a clinical trial conducted nearly 30 years ago in
patients with mild or moderate airflow limitation, in which those
younger than 60 years tended to have a greater response to al-
buterol, whereas individuals older than 60 years tended to have a
greater response to ipratropium.5 However, the study recruitedboth patients with asthma and those with chronic obstructive
pulmonary disease from general medical practice settings. In the
subgroup of patients with asthma, although there was a slight
trend to decreasing efficacy with age for albuterol, age had no
significant influence on the efficacy of ipratropium.5 Similarly, in
a study that only evaluated patients with asthma, although the
efficacy of both albuterol and ipratropium was lower in older
than younger patients, within each age group responses to
albuterol and ipratropium were similar.17 Likewise, in a study
that recruited patients with stable asthma, both albuterol and
ipratropium were effective in younger (18-25 years) and older
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either drug.18 These studies demonstrate the importance of
recruiting appropriate patient populations; all of the MezzoTinA-
asthma studies (which used medium-dose ICS) and PrimoTinA-
asthma studies (which used high-dose ICS plus long-acting
bronchodilators) specifically recruited patients with asthma,
excluding those with chronic obstructive pulmonary disease, and
showed results that were consistent with previous asthma studies
that used short-acting bronchodilators. The MezzoTinA-asthma
data extend and expand these previous data using 2 long-acting
bronchodilators: tiotropium showed similar effectiveness across
the age groups studied in terms of both lung function and
asthma control, with the effectiveness of salmeterol on lung
function not impacted by age. Importantly, all treatments were
well tolerated, with adverse event profiles similar to placebo
without evidence that side effects varied with age.
The main limitation of the analyses in this study is the vari-
ation in sizes of the patient subgroups, and especially the rela-
tively small sizes of the younger than 40 years category in the 2
PrimoTinA-asthma studies and the older than 60 years category
in the 2 MezzoTinA-asthma studies. However, the consistency of
the tiotropium data across all end points in the 2 pairs of studies
suggest that our findings are unlikely to be substantially impacted
by the sizes of these subgroups. In addition, these analyses were
not formally powered, and lack of statistical significance of a
treatment-by-age subgroup interaction from such analyses should
be interpreted with caution. A prospective, suitably designed
study would be required to confirm the findings. Of course, care
should be taken when extrapolating the data from any ran-
domized controlled trial (where inclusion and exclusion criteria
were applied to select patients) to real life.
CONCLUSIONS
Once-daily tiotropium add-on to ICS or ICS/LABA therapy
improved lung function and was effective and well tolerated in
patients with symptomatic asthma independent of age. The an-
alyses clearly show that the bronchodilator effects of anti-
muscarinic therapy with tiotropium are similar in younger and
older patients, and so provide evidence that differs from the
perception that there is a reduced bronchodilator response in the
elderly. These findings have important therapeutic implications,
because there is an increase in the aging population worldwide as
well as increased prevalence of asthma in older individuals.
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DOHERTY ETAL 2660.e1ONLINE REPOSITORYTABLE E1. ACQ total score and responders at week 24 in patients with severe asthma (PrimoTinA-asthma)
Age group Tiotropium Respimat 5 mg QD Placebo
<40 y
Adjusted mean  SE 1.934  0.093 (N ¼ 61) 2.214  0.094 (N ¼ 60)
Active-placebo difference, adjusted mean (95% CI; P value)* e0.280 (e0.540 to e0.021; .0341)
Patients with a clinically relevant improvement,† n/N (%) 36/69 (52.2) 26/67 (38.8)
40-60 y
Adjusted mean  SE 2.038  0.046 (N ¼ 241) 2.156  0.048 (N ¼ 224)
Active-placebo difference, adjusted mean (95% CI; P value)* e0.118 (e0.250 to 0.013; .0766)
Patients with a clinically relevant improvement,† n/N (%) 137/256 (53.5) 114/238 (47.9)
>60 y
Adjusted mean  SE 1.991  0.059 (N ¼ 121) 2.153  0.055 (N ¼ 141)
Active-placebo difference, adjusted mean (95% CI; P value)* e0.163 (e0.321 to e0.004; .0444)
Patients with a clinically relevant improvement,† n/N (%) 71/128 (55.5) 73/149 (49.0)
QD, Once daily; SE, standard error.
Full analysis set. Pooled data: add-on to ICS plus LABA. N is the number of patients with measurements at the respective time point.
*Interaction P value .13.
†Defined as an improvement in ACQ score of at least 0.5 points from baseline.







50 mg BID Placebo
<40 y
Adjusted mean  SE 1.314  0.048 (N ¼ 193) 1.347  0.050 (N ¼ 178) 1.197  0.045 (N ¼ 219) 1.483  0.047 (N ¼ 196)
Active-placebo difference, adjusted
mean (95% CI; P value)*
e0.169 (e0.301 to e0.037; .0121) e0.136 (e0.271 to e0.001; .0482) e0.286 (e0.414 to e0.158; <.0001)
Patients with a clinically relevant
improvement,† n/N (%)
132/208 (63.5) 127/192 (66.1) 162/234 (69.2) 120/216 (55.6)
40-60 y
Adjusted mean  SE 1.367  0.043 (N ¼ 252) 1.439  0.044 (N ¼ 245) 1.407  0.044 (N ¼ 242) 1.534  0.044 (N ¼ 246)
Active-placebo difference, adjusted
mean (95% CI; P value)*
e0.167 (e0.287 to e0.046; .0067) e0.095 (e0.216 to 0.026; .1219) e0.127 (e0.248 to e0.006; .0405)
Patients with a clinically relevant
improvement,† n/N (%)
168/257 (65.4) 160/258 (62.0) 162/250 (64.8) 150/254 (59.1)
>60 y
Adjusted mean  SE 1.473  0.098 (N ¼ 47) 1.463  0.088 (N ¼ 59) 1.458  0.098 (N ¼ 48) 1.568  0.101 (N ¼ 45)
Active-placebo difference, adjusted
mean (95% CI; P value)*
e0.095 (e0.372 to 0.182; .4997) e0.106 (e0.369 to 0.158; .4308) e0.110 (e0.387 to 0.167; .4362)
Patients with a clinically relevant
improvement,† n/N (%)
32/50 (64.0) 43/63 (68.3) 32/51 (62.7) 29/48 (60.4)
BID, Twice daily; QD, once daily.
Full analysis set. Pooled data: add-on to ICS. N is the number of patients with measurements at the respective time point.
*Interaction P value .49.









































FIGURE E1. Adjusted mean peak FEV1 and treatment-placebo differences at week 24 in patients with (A) severe asthma (PrimoTinA-
asthma) and (B) moderate asthma (MezzoTinA-asthma). BID, Twice daily; QD, once daily. Full analysis set. Pooled data: (A) add-on to ICS
plus LABA; (B) add-on to ICS. Data plotted are adjusted mean  SE.
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FIGURE E2. Adjusted mean trough FVC and treatment-placebo differences at week 24 in patients with (A) severe asthma (PrimoTinA-
asthma) and (B) moderate asthma (MezzoTinA-asthma). BID, Twice daily; FVC, forced vital capacity; QD, once daily. Full analysis set.
Pooled data: (A) add-on to ICS plus LABA; (B) add-on to ICS. Data plotted are adjusted mean  SE.
J ALLERGY CLIN IMMUNOL PRACT
SEPTEMBER 2020
2660.e4 DOHERTY ETAL
